Tokyo-Sana
Japan has started clinical trials of a vaccine against the Corona virus that requires a lower dose than the existing vaccines.
The Japanese broadcaster NHK reported that the Japanese company VLP Therapeutics has started clinical trials on the vaccine, which uses RNA and makes the flow of genetic information possible.
The company hopes that the vaccine will become available before the end of 2022, and the company pointed out that the first phase of the experiment began in a hospital, and this is the fifth company to conduct clinical trials on locally developed Corona virus vaccines in Japan.
